Treatment with Neuraminidase inhibitors (e.g. zanamivir, oseltamivir). No studies conducted, and therefore no data exists on benefits. Seems safe for Oseltamivir. Mild known side effects, including vomiting. Zanamivir may evoke asthma attacks and is risky for children with Cystic Fibrosis.
Do not use this treatment:
No data exists on the benefits. Side effects seem mild for Oseltamivir, while Zanamivir is risky for CF patients.
Works best if taken within 2 days of having flu symptoms, and should be taken for 5 consecutive days.
For example: Oseltamivir (Tamiflu), Zanamivir (Relenza)
Children with Cystic Fibrosis, 2 to 16 years old
Varies according to age, weight and treatment. Oseltamivir usually 2 mg/kg, twice-daily, for 5 days. Zanamivir usually 10 mg, twice-daily, for 5 days.
Treatment of Influenza infection, symptoms and complications
Unknown. No valid clinical trials.
Common side effects include vomiting, diarrhea, nausea, headache, nosebleeds and trouble sleeping. Rare side effects may include psychiatric symptoms, trouble breathing and seizures. Zanamivir is risky for children with Cystic Fibrosis, as it may lead to Asthma attacks.
Flu (influenza virus infection and symptoms).
Symptoms and signs:
Cough, dizziness, fever, headache, nausea, pains, runny nose, sore throat, vomiting and aches.
Ear infection, lung infection, Seizures.
Visitors at this page also visited
Neuraminidase inhibitors (NAIs) are a class of drugs which block the neuraminidase enzyme. They are commonly used as antiviral drugs because they block the function of viral neuraminidases of the influenza virus, by preventing its reproduction by budding from the host cell. Oseltamivir (Tamiflu) a prodrug, Zanamivir (Relenza), Laninamivir (Inavir), and Peramivir belong to this class. (source)
Similar pages on this site
Good to know
Can we eat to starve cancer?
William Li, Head of the Angiogenesis Foundation
Can we use VR to diagnose the cause of pain?
Introducing an article about the lessons learned so far from VR Therapy attempts
How Health Care Changes When Algorithms Start Making Diagnoses
Andrew BurtSamuel Volchenboum, HBR